We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

219 hedge funds and large institutions have $3.78B invested in Blueprint Medicines in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 56 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more call options, than puts

Call options by funds: $90.8M | Put options by funds: $29.4M

55% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 56

3.21% more ownership

Funds ownership: 101.52% → 104.73% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

0% less funds holding

Funds holding: 220 → 219 (-1)

19% less capital invested

Capital invested by funds: $4.68B → $3.78B (-$898M)

Holders
219
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
4.8%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
29
Increased
87
Reduced
56
Closed
29
Calls
$90.8M
Puts
$29.4M
Net Calls
+$61.4M
Net Calls Change
+$37.8M

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadian Capital Management
New York
+$77.4M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$21.7M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.3M
4
HM
HealthCor Management
New York
+$19.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.2M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$28.5M
2
Invesco
Invesco
Georgia
-$24.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$21.1M
4
AG
Artal Group
Luxembourg
-$13M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nomura Holdings
226
Nomura Holdings
Japan
– -$1.21M -12,500 Closed
SAM
227
Sectoral Asset Management
Quebec, Canada
– -$1.04M -10,984 Closed
Stifel Financial
228
Stifel Financial
Missouri
– -$983K -10,415 Closed
USAA
229
United Services Automobile Association
Texas
– -$733K -7,770 Closed
PVAM
230
Pacific View Asset Management
California
– -$463K -4,925 Closed
BFM
231
Boothbay Fund Management
New York
– -$462K -4,900 Closed
FRM
232
Fox Run Management
Connecticut
– -$335K -3,550 Closed
ACM
233
Adalta Capital Management
New York
– -$309K -3,275 Closed
GAM
234
Gotham Asset Management
New York
– -$248K -2,631 Closed
HSBC Holdings
235
HSBC Holdings
United Kingdom
– -$238K -2,521 Closed
TI
236
Trexquant Investment
Connecticut
– -$203K -2,156 Closed
Walleye Trading
237
Walleye Trading
New York
– -$65.5K -758 Closed
Parallax Volatility Advisers
238
Parallax Volatility Advisers
California
– -$58K -616 Closed
MWM
239
Mascoma Wealth Management
New Hampshire
– -$14K -150 Closed
PCP
240
Proficio Capital Partners
Massachusetts
– -$11K -116 Closed
NCM
241
Next Capital Management
New York
– -$6K -65 Closed
WCM
242
Whitener Capital Management
North Carolina
– -$3K -37 Closed
BWA
243
BDO Wealth Advisors
Florida
– -$3K -33 Closed
CAW
244
Cornerstone Advisors (Washington)
Washington
– -$1K -12 Closed
FGAM
245
Financial Gravity Asset Management
Texas
– +$86 +1 New
GAM
246
Gemmer Asset Management
California
– +$86 +1 New
GGHC
247
Gilder Gagnon Howe & Co
New York
– +$346 +4 New
6 7 8 9
10

BPMC Hedge Fund Activity: Q3 2019 in Review

219 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2019, worth a combined $3.78B — down 19% from $4.68B a quarter earlier.

Fund positioning in BPMC was balanced in Q3 2019: 29 funds opened new positions, 29 closed out, 87 added to existing stakes and 56 trimmed.

The largest buyer was Cadian Capital Management, adding an estimated $77.4M. The largest seller was Perceptive Advisors, cutting an estimated $28.5M.

  • 219 institutional investors held Blueprint Medicines (BPMC) as of Q3 2019, down from 220 in Q2 2019.
  • Funds reported $3.78B of Blueprint Medicines stock for Q3 2019, down 19% quarter-over-quarter.
  • 29 funds opened new Blueprint Medicines positions in Q3 2019 and 29 closed out, a net change of 0 holders.
  • The largest Blueprint Medicines buyer in Q3 2019 was Cadian Capital Management, an estimated $77.4M added.
  • The largest Blueprint Medicines seller in Q3 2019 was Perceptive Advisors, an estimated $28.5M sold.

Based on aggregated 13F filings for Q3 2019.